The analysis of nearly 8,800 patients assessed pacemaker, implantable cardioverter defibrillator and cardiac resynchronisation therapy device data from subjects monitored using the Medtronic CareLink remote monitoring system. Reactive ATP therapy was associated with a significant decrease in atrial fibrillation events compared to a matched control group, with Reactive ATP patients experiencing a 38 percent reduction in persistent atrial fibrillation events, regardless of patient age, sex or device type. Dr Rob Kowal, vice-president and chief medical officer of Medtronic's cardiac rhythm and heart failure division, said: "Physicians have been asking how the CareLink Network data can be leveraged to gain real-world insights into the benefits of our therapies. This study does exactly that."